Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2021)
13 slides from Nova Eye Medical's shareholder meeting presentation, Nov 24, 2021
Slide 1: Nova Eye Medical Limited (ASX:EYE) Annual General Meeting
1 Nova Eye Medical Limited (ASX:EYE) Annual General Meeting 24 November 2021
Slide 2: Disclaimer
2 DISCLAIMER: This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any
Slide 3: ASX:EYE Business Snapshot
3 ASX:EYE BUSINESS SNAPSHOT Nova Eye Medical Limited (ASX:EYE) comprises two business units, Glaucoma and AMD/2RT® – these segments address the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Strategy Progress 2RT® to market-ready status Develop, market a
Slide 4: Glaucoma Market Strong Growth Theme
4 GLAUCOMA MARKET STRONG GROWTH THEME Glaucoma is the leading cause of irreversible blindness and the second leading cause of blindness worldwide. The aging global population is driving glaucoma prevalence and provides a strong platform for business growth. 134.2 million 1 Advancements in diagnost
Slide 5: A Glaucoma Operating Result
5 A GLAUCOMA OPERATING RESULT Material improvement in operating result was underpinned by a 25% increase in global sales compared to the pcp, including the addition of Molteno3® sales, and a reduction in operating costs. A$’000s (year ended 30 June) US$’000s (year ended 30 June)1 FY20 FY21 Growth FY
Slide 6: Recent Glaucoma Market Developments
6 RECENT GLAUCOMA MARKET DEVELOPMENTS The iTrackTM microcatheter with its patented features is the original canaloplasty device. GROWING MARKET WITH Stent-free, tissue sparing intervention INCREASED COMPETITION, Reimbursement in USA without (and with) concurrent cataract surgery; stent-based MIG
Slide 7: FY22 Glaucoma Sales Update and Outlook
7 FY22 GLAUCOMA SALES UPDATE AND OUTLOOK GLAUCOMA GROWTH Global sales for the four months ended 31 October 2021 are CONTIGENT ON A$4.1m. This is growth of 4% compared with PCP in constant currency. NEXT GEN ITRACK™ Sales outside the USA have grown 75% due to investment in German market. GERMANY
Slide 8: 2RT®, Intermediate AMD
8 2RT®, INTERMEDIATE AMD 2RT® (AlphaRET) is a proprietary, world-first nanosecond laser therapy to treat intermediate AMD (iAMD). While there have been major advances in the treatment of AMD in its late stages (referred to as Wet AMD), there has been little progress in the treatment of AMD in its ea
Slide 9: Roadmap Pivotal Study
9 2RT® is a subthreshold nano-pulse non-thermal laser and has a method of action unlike any ophthalmic laser in use today ROADMAP PIVOTAL STUDY Investigational Device Exemption (IDE) application PRE-CLINCAL WORK with the US Food and Drug Administration (FDA) lodged in early July 2021 to commence a
Slide 10: 2RT® Market Assessment
10 Our proprietary 2RT® nanosecond laser therapy is a world-first intervention designed to treat intermediate AMD (iAMD). There is currently no treatment (drugs or devices) for the treatment of iAMD. 2RT® MARKET ASSESSMENT Population with Patients who do not meet 2RT® Estimated population with Early
Slide 11: Estimated Revenue Opportunity for 2RT®
11 Subject to the completion of a pivotal study or similar to confirm ESTIMATED REVENUE results of the LEAD study (77% reduction in rate of progression OPPORTUNITY FOR 2RT® to late-stage AMD in select patients with iAMD) the opportunity is very large. Business model comprising 1. capital equipme
Slide 12: Q&A
12 Q&A
Slide 13: Contacts
13 CONTACTS Mr Tom Spurling Dr Tom Duthy Ms Kate Hunt Managing Director Investor Relations and Head of Marketing +61 417 818 658 Corporate Development +61 404 080 679 tspurling@nova-eye.com +61 402 493 727 khunt@nova-eye.com tduthy@nova-eye.com C O M P AN Y INVESTORS C O M P AN Y
Nova Eye Medical — Shareholder Meeting (November 2021) on 6ix